35 terminated. 35 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Terminated 35 |
| Phase 1 | 4 | Terminated 4 |
| Phase 3 | 3 | Terminated 3 |
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder NRCT-101SR, NRCT-202XR - ADHD | Phase 2 | Terminated | Neurocentria, Inc. | 2 | 2025-02-25 | 2026-01-15 |
| Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD NRCT-101SR - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 2 / Phase 3 | Terminated | Neurocentria, Inc. | 95 | 2024-01-25 | 2026-01-15 |
| Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD Cannabis oil - ADHD, Hyperactivity | Phase 2 | Terminated | Brlev Agricultural Crops Ltd | 8 | 2022-07-31 | 2023-04-25 |
| INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD INP105, Placebo - Agitation in Adolescents and Young Adults With ASD | Phase 2 | Terminated | Impel Pharmaceuticals | 8 | 2022-06-23 | 2023-09-28 |
| Atomoxetine in Patients With Tourette's Syndrome Atomoxetine - Tourette Syndrome | Phase 2 | Terminated | Poitiers University Hospital | 5 | 2022-05-31 | 2024-01-23 |
| Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia Famotidine, Speech Language Therapy - Laryngomalacia, Gastro Esophageal Reflux | Phase 1 / Phase 2 | Terminated | Reema Padia | 65 | 2020-11-18 | 2025-07-20 |
| Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder GWP42006 - Autism Spectrum Disorder | Phase 2 | Terminated | Jazz Pharmaceuticals | 1 | 2020-01-07 | 2022-09-02 |
| Investigation of Mechanisms of Action in Superpower Glass Superpower Glass - Autism Spectrum Disorder, Autism | Phase 1 / Phase 2 | Terminated | Stanford University | 20 | 2019-09-04 | 2023-09-05 |
| Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task - Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression | Phase 2 | Terminated | Supernus Pharmaceuticals, Inc. | 7 | 2019-05-30 | 2025-05-02 |
| Impact of Combined Medication and Behavioral Treatment for ASD & ADHD Amphetamine, ESDM informed parent coaching, Placebo Oral Tablet - Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder | Phase 2 | Terminated | Duke University | 18 | 2018-12-14 | 2022-03-22 |
| Translating Neuroprediction Into Precision Medicine Via Brain Priming Oxytocin, Pivotal Response Treatment, Placebo - Autism Spectrum Disorder | Phase 2 | Terminated | Yale University | 5 | 2018-12-07 | 2022-08-09 |
| Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome NBI-98854 - Tourette Syndrome | Phase 2 | Terminated | Neurocrine Biosciences | 6 | 2018-10-17 | 2022-04-19 |
| Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome Valbenazine, Placebo oral capsule - Tourette Syndrome | Phase 2 | Terminated | Neurocrine Biosciences | 81 | 2018-04-17 | 2022-05-17 |
| Safety and Efficacy of Cannabis in Tourette Syndrome Cannabis - Tourette Syndrome | Phase 2 | Terminated | University Health Network, Toronto | 15 | 2018-01-15 | 2021-01-25 |
| A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD) Placebo, RO5285119 - Autism Spectrum Disorder | Phase 2 | Terminated | Hoffmann-La Roche | 339 | 2016-11-21 | 2021-02-08 |
| Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders Melatonin and Donepezil, Placebo - Autism Spectrum Disorder | Phase 2 | Terminated | Stony Brook University | 12 | 2015-06-01 | 2024-06-06 |
| Oxytocin in Adolescents With Autism Spectrum Disorders OCYTOCINA - SPRAY NASAL - Autism Spectrum Disorder | Phase 2 / Phase 3 | Terminated | University of Sao Paulo General Hospital | 30 | 2015-06-01 | 2019-10-28 |
| Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI methylphenidate, Placebo - Traumatic Brain Injury | Phase 2 | Terminated | Uniformed Services University of the Health Sciences | 11 | 2014-09-01 | 2018-10-04 |
| Evaluating Anodal tDCS Preceding Aphasia Therapy transcranial direct current stimulation - Stroke, Aphasia | Phase 1 / Phase 2 | Terminated | Northwell Health | 15 | 2014-09-01 | 2021-04-05 |
| Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) Trial Highly unsaturated omega-3 fatty acids - Attention Deficit Disorder, Attention Deficit Hyerpactivity Disorder | Phase 2 | Terminated | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 63 | 2014-06-04 | 2018-12-26 |
Showing 20 of 35. Sign in to see all of them.
Autism Spectrum Disorder (15) · Attention Deficit Disorder with Hyperactivity (11) · Autistic Disorder (11) · Tourette Syndrome (4) · Asperger Syndrome (3) · Child Development Disorders, Pervasive (2) · Communication Disorders (2) · Spasm (2) · Aphasia (1) · Apraxias (1) · Behavior (1) · Brain Injuries, Traumatic (1) · Cocaine-Related Disorders (1) · Gastroesophageal Reflux (1) · Impulsive Behavior (1)
Mental Disorders (35) · Child Development Disorders, Pervasive (16) · Attention Deficit and Disruptive Behavior Disorders (11) · Nervous System Diseases (11) · Neurologic Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Brain Diseases (6) · Central Nervous System Diseases (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Basal Ganglia Diseases (4) · Genetic Diseases, Inborn (4) · Heredodegenerative Disorders, Nervous System (4) · Movement Disorders (4)
Amphetamine (2) · Donepezil (2) · Oxytocin (2) · Transcranial Magnetic Stimulation (2) · nabiximols (2) · valbenazine (2) · Aripiprazole (1) · Atomoxetine Hydrochloride (1) · Equipment and Supplies (1) · Famotidine (1) · Fatty Acids, Omega-3 (1) · Fish Oils (1) · Insulin-Like Growth Factor I (1) · Leucovorin (1) · Magnetic Resonance Imaging (1)
National Institute of Mental Health (NIMH) (2) · Neurocentria, Inc. (2) · Neurocrine Biosciences (2) · New York State Psychiatric Institute (2) · Abbott (1) · Brainsway (1) · Brlev Agricultural Crops Ltd (1) · Coronado Biosciences, Inc. (1) · Duke University (1) · Eli Lilly and Company (1) · Forest Laboratories (1) · Hadassah Medical Organization (1) · Hoffmann-La Roche (1) · Icahn School of Medicine at Mount Sinai (1) · Impel Pharmaceuticals (1)
United States (29) · Canada (3) · Israel (3) · Puerto Rico (3) · France (2) · Belgium (1) · Brazil (1) · Colombia (1) · Estonia (1) · Hungary (1) · Iceland (1) · Italy (1) · New Zealand (1) · Poland (1) · Serbia (1)
Alexander Kolevzon, MD (1) · Alexandra Sporn, MD (1) · Ashura W Buckley, M.D. (1) · Craig Erickson, MD (1) · David V Herin, Ph.D (1) · Denis Sukhodolsky, Ph.D. (1) · Dennis P Wall, PhD (1) · Eric Wassermann, MD (1) · Gagan Joshi, MD (1) · Geraldine Dawson, PhD (1) · Guosong Liu, MD, PhD (1) · Guy Bar-Klein, PhD (1)
PMID 25733754, PMID 26493637, PMID 27752075, PMID 28576350, PMID 35793101, PMID 36006807, PMID 36040329, PMID 37267443, PMID 37811711, PMID 40351246, PMID 40762274
2019 (1), P30MH071478 (1), P50DA009262 (1), P50HD093074 (1)